Researchers used AI to identify fungal peptides that taste salty or boost saltiness, aimed at cutting sodium in food. A food science find rather than a drug story.
Recap by typeshit. Full story at Nature.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
The 1,200-person trial starts next year with MIT and Pitt researchers, funded by a $13 million Arnold Ventures grant, and will also track housing and jobs.
Researchers found the peptide they built as a treatment already circulates in human blood, at lower levels in people with cognitive impairment.
Lilly Medical points to newly published results from a double-blind, placebo-controlled phase 3 study of its triple-hormone shot in people with diabetes.
A sponsored-style look at compounded tirzepatide and semaglutide through telehealth firm Mochi Health, noting compounded drugs aren't FDA approved for safety or quality.
Among the items: Walmart plans free GLP-1 diabetes drugs for employees in 2027, and Verdiva Bio dropped a phase II oral GLP-1 study citing market changes.
Loading…